Atai Beckley N.V.

Atai Beckley N.V. (ATAI) priced its initial public offering on Jun 21, 2021 at $15.00 per share, within its $13.00–$15.00 range, raising $225M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $2.29B. Credit Suisse was lead-left underwriter, joined by Citigroup, TD Cowen and Cantor and others. Dentons and Latham & Watkins advised the company and Davis Polk advised the underwriters.

Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on treatments for mental health disorders. It was built from atai Life Sciences, founded in 2018, and has a pipeline of development programs and enabling technologies, including psychedelic compounds and digital therapeutics.

Status

IPO

Ticker

ATAI

Exchange

Nasdaq Global Market

Priced

Jun 21, 2021

IPO price

$15.00

Price range

$13.00–$15.00

Raised

$225M

Market cap at IPO price

$2.29B

First filed

Apr 20, 2021

Underwriters

Credit Suisse, Citigroup, TD Cowen, Cantor, RBC Capital Markets and Canaccord Genuity

Company counsel

Dentons and Latham & Watkins

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.